Evidence map›Paper›PMID 30498340›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan.

Ryosuke Hirano, Masaki Fujita, Takemasa Matsumoto, Rintaro On, Kentaro Watanabe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. A New Prognostic Index PDPI for the Risk of Pneumonia Among Patients With Diabetes.Frontiers in cellular and infection microbiology · 2021
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ryosuke HiranoDepartment of Respiratory Medicine, Fukuoka University Hospital, Nanakuma, Jonanku, Fukuoka, Japan, mfujita@fukuoka-u.ac.jp.
Masaki FujitaDepartment of Respiratory Medicine, Fukuoka University Hospital, Nanakuma, Jonanku, Fukuoka, Japan, mfujita@fukuoka-u.ac.jp.
Takemasa MatsumotoDepartment of Respiratory Medicine, Fukuoka University Hospital, Nanakuma, Jonanku, Fukuoka, Japan, mfujita@fukuoka-u.ac.jp.
Rintaro OnDepartment of Respiratory Medicine, Fukuoka University Hospital, Nanakuma, Jonanku, Fukuoka, Japan, mfujita@fukuoka-u.ac.jp.
Kentaro WatanabeDepartment of Respiratory Medicine, Fukuoka University Hospital, Nanakuma, Jonanku, Fukuoka, Japan, mfujita@fukuoka-u.ac.jp.
Fukuoka University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) decreases the frequency of COPD exacerbations. Recently, pneumonia was reported as a complication of ICS in patients with COPD. However, there have been few reports concerning the relationship between ICS and pneumonia in Japan. Moreover, there is little information on the types of ICS. PATIENTS AND

methodsTo clarify these issues, we investigated the occurrence of pneumonia in Japanese patients with COPD. We retrospectively investigated the occurrence of pneumonia in patients with COPD in our hospital from January 2009 to August 2013. Morbidity and mortality, ICS use, age, sex, and COPD classification were investigated. A group of patients with COPD who received ICS and a group of patients with COPD who did not receive ICS were compared each other.

resultsFifty-one patients developed pneumonia among 639 (7.98%) patients with COPD. Among 252 ICS-treated patients with COPD, 13 (5.16%) developed pneumonia, and among 387 ICS-untreated patients with COPD, 38 (9.82%) developed pneumonia. The mortality rate in ICS-treated patients with COPD was 7.7%, while that in ICS-untreated patients was 10.5% (

conclusionICS might not increase the risk of pneumonia in Japanese patients with COPD. In regard to pneumonia, ICS can be safely used in Japanese patients with COPD. Because there are apparent differences in lung diseases among races, appropriate treatment should be investigated in each country.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdultAgedAged, 80 and overAsian PeopleDisease ProgressionFemaleHumansIncidenceJapanLungMaleMiddle AgedPneumoniaPulmonary Disease, Chronic ObstructiveAdrenal Cortex Hormonesadverse eventCOPDinhaled corticosteroidpneumonia

Identifiers

PMID30498340
PMCPMC6207395
OpenAlexW2896984748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.